Fidelity Disruptive Medicine ETF
Fidelity Disruptive Medicine ETF (NASDAQ: FMED) is an exchange-traded fund listed on NASDAQ, trading at $32.87 (about ₹3,088 a unit) as of 9 Nov 2026, 4:00 PM ET. It has an expense ratio of 0.5% and holds 63 securities. Indian residents can buy FMED through Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$31.91
Today's high
$33.00
52 week low
$23.48
52 week high
$33.56
FMED opened at $32.13, closed previously at $31.64, and has traded between $23.48 and $33.56 over the past 52 weeks.
About
This exchange-traded fund allocates capital to pioneering enterprises reshaping medical detection, treatments, and care delivery, encompassing areas from genetic manipulation to automated surgical procedures and online health ecosystems.
Key statistics
Expense ratio
0.5%
Assets (AUM)
$52.7M
Holdings
63
NAV
$31.64
Avg. volume
15.39K
1-year price change
+28.87%
5-year price change
—
Price change excludes dividends.
Top 10 holdings
FMED holds 63 securities in total. These 10 are 44.3% of the fund.
Where the money is invested
Countries
How to buy FMED from India
Indian residents can buy FMED units through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the units are held in your own name with Interactive Brokers. Read the full guide: how to invest in FMED from India
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Search FMED and buy
Find the fund by its ticker, FMED, on NASDAQ, and place your order. Fractional units are available and there is no minimum trade size, so you can buy by amount.
Track holdings and download tax reports
Follow your FMED position in USD and INR, and use Paasa's tax statements when you file your Indian return.
Trading and taxes when buying FMED from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on foreign ETF units held for more than 24 months are long-term and taxed at 12.5% without indexation. Gains on units held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
FAQs
What is the FMED price today?
Fidelity Disruptive Medicine ETF (FMED) last traded at $32.87 on NASDAQ, as of 9 Nov 2026, 4:00 PM ET. That is ₹3,088 a unit at the 9 Nov 2026 USD/INR rate.
When does FMED trade, in Indian time?
NASDAQ trades 8:00 pm – 2:30 am IST, so the close lands after midnight. The window shifts to 7:00 pm – 1:30 am IST when the US is on daylight time. Orders can only execute during that window.
How big is FMED, and what does it cost to hold?
Fidelity Disruptive Medicine ETF manages about $52.7M. Its expense ratio is 0.5% a year, deducted inside the fund. It launched in 2020.
What are FMED's largest holdings?
The top three are 10X GENOMICS INC (6.4%), LIFESTANCE HEALTH GROUP INC (5.2%) and ARGENX SE SPONSORED ADR (4.9%). FMED's 10 largest positions make up 44.3% of the fund.
How are gains on FMED taxed in India?
Units held for more than 24 months are long-term and taxed at 12.5% without indexation; units held for 24 months or less are taxed at your income-tax slab rate. The gain is worked out in rupees, so the currency move counts.
Can I buy fractional units of FMED?
Yes. You can buy FMED by amount rather than by whole unit, and there is no minimum trade size.
How has FMED performed?
FMED's price is up 28.9% over the past year. These figures are price change only and exclude dividends; past performance does not guarantee future returns.